Market open
Treace Medical Concepts/$TMCI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Treace Medical Concepts
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Ticker
$TMCI
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
477
Website
TMCI Metrics
BasicAdvanced
$490M
-
-$0.90
0.78
-
Price and volume
Market cap
$490M
Beta
0.78
52-week high
$12.74
52-week low
$3.92
Average daily volume
417K
Financial strength
Current ratio
4.621
Quick ratio
3.352
Long term debt to equity
61.333
Total debt to equity
61.699
Interest coverage (TTM)
-10.59%
Management effectiveness
Return on assets (TTM)
-14.83%
Return on equity (TTM)
-44.45%
Valuation
Price to revenue (TTM)
2.323
Price to book
4.33
Price to tangible book (TTM)
5.31
Price to free cash flow (TTM)
-9.974
Growth
Revenue change (TTM)
11.89%
Earnings per share change (TTM)
10.58%
3-year revenue growth (CAGR)
30.40%
3-year earnings per share growth (CAGR)
28.06%
What the Analysts think about TMCI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Treace Medical Concepts stock.
TMCI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TMCI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TMCI News
AllArticlesVideos
Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference
GlobeNewsWire·1 week ago
Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference
GlobeNewsWire·1 week ago
An Investigation Has Been Launched Into Treace Medical Concepts, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Treace Medical Concepts stock?
Treace Medical Concepts (TMCI) has a market cap of $490M as of April 04, 2025.
What is the P/E ratio for Treace Medical Concepts stock?
The price to earnings (P/E) ratio for Treace Medical Concepts (TMCI) stock is 0 as of April 04, 2025.
Does Treace Medical Concepts stock pay dividends?
No, Treace Medical Concepts (TMCI) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Treace Medical Concepts dividend payment date?
Treace Medical Concepts (TMCI) stock does not pay dividends to its shareholders.
What is the beta indicator for Treace Medical Concepts?
Treace Medical Concepts (TMCI) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.